Laboratory monitoring of drugs at initiation of therapy in ambulatory care Authors
Received: 27 May 2005 Revised: 08 August 2005 Accepted: 08 August 2005 DOI:
Cite this article as: Raebel, M.A., Lyons, E.E., Andrade, S.E. et al. J GEN INTERN MED (2005) 20: 1120. doi:10.1111/j.1525-1497.2005.0257.x Abstract Product labeling and published guidelines reflect the importance of monitoring laboratory parameters for drugs with a risk of organ system toxicity or electrolyte imbalance. Limited information exists about adherence to laboratory monitoring recommendations. The objective of this study was to describe laboratory monitoring among ambulatory patients dispensed medications for which laboratory testing is recommended at therapy initiation. BACKGROUND AND OBJECTIVES: We conducted a retrospective cross-sectional analysis of patients in 10 geographically distributed health maintenance organizations who were newly prescribed medications with recommended laboratory test monitoring. The main outcome measure was the proportion of initial drug dispensing without recommended baseline laboratory monitoring for 35 newly initiated drugs or drug classes. DESIGN AND SUBJECTS: One hundred seven thousand, seven hundred sixty-three of 279,354 (39%) initial drug dispensings occurred without recommended laboratory monitoring. Patients without monitoring were younger than patients who had monitoring (median 57 vs 61 years, RESULTS: P<.001). Thirty-two percent of dispensings where a serum creatinine was indicated did not have it evaluated (range across drugs, 12% to 61%); 39% did not have liver function testing (range 10% to 75%); 32% did not have hematologic monitoring (range 9% to 51%); and 34% did not have electrolyte monitoring (range 20% to 62%) ( P<.001). Substantial opportunity exists to improve laboratory monitoring of drugs for which such monitoring is recommended. This study emphasizes the need for research to identify the clinical implications of not conducting recommended laboratory monitoring, existing barriers to monitoring, and methods to improve practice. CONCLUSIONS: Key Words laboratory monitoring ambulatory drug therapy
The authors have no conflicts of interest to declare for this article.
Authors had access to study data, take responsibility for the accuracy of the analysis, and had authority over manuscript preparation and the decision to submit the manuscript for publication.
Previous Presentation: Portions of this work were presented during the HMO Research Network 10th Annual Meeting on May 5, 2004, in Dearborn, Mich.
Funding/Support and Role of Sponsor: This work was supported by a cooperative agreement (U18 HS 11832) from the Agency for Healthcare Research and Quality (AHRQ). AHRQ did not design or conduct the study, collect, management, analyze, or interpret the data, nor did it have a role in the preparation, review, or approval of the manuscript.
Bates DW, Boyle DL, Vander Vliet MB, et al.
Relationship between medication errors and adverse drug events. J Gen Intern Med. 1995;10:199–205.
Kohn LT, Corrigan JM, Donaldson MS, eds. To Err is Human: Building a Safer Health System. Washington, DC: Committee on Quality of Health Care in American, Institute of Medicine. National Academy Press; 1999.
Lazarou J, Pomeranz BH, Corey PH
. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.
Bates DW, Cullen DJ, Laird N, et al.
Incidence of adverse drug events and potential adverse drug events. JAMA. 1995;274:29–34.
Bates DW, Leape LL, Cullen DJ, et al.
Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998;280:1311–6.
Classen DC, Pestotnik SL, Evans RS, et al.
Adverse drug events in hospitalized patients. JAMA. 1997;277:301–6.
Leape LL, Brennan TA, Laird N, et al.
The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324:377–84.
Leape LL, Bates DW, Cullen DJ, et al.
Systems analysis of adverse drug events. JAMA. 1995;274:35–43.
Schneeweiss S, Hasford J, Gottler M, et al.
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58:285–91.
Gandhi TK, Burstin HR, Cook EF, et al.
Drug complications in outpatients. J Gen Intern Med. 2000;15:149–54.
Hanlon JT, Schmader KE, Koronkowski MJ, et al.
Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45:945–8.
Hutchinson TA, Flegal KM, Kramer MS, et al.
Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis. 1986;39:533–42.
Gandhi TK, Weingart SN, Borus J, et al.
Patient safety adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556–64.
Gurwitz JH, Field TS, Harrold LR, et al.
Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107–16.
Steiner JF, Robbins LJ, Hammermeister KE, et al.
Incidence of digoxin toxicity in outpatients. West J Med. 1994;161:474–8.
Johnson JA, Bootman JL
. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155:1949–56.
Kennedy AG, MacLean CD
. Clinical inertia: errors of omission in drug therapy. Am J Health-Syst Pharm. 2004;61:401–4.
Leape LL, Lawthers AG, Brennan TA, Johnson WG. Preventing medical injury. Qual Rev Bull. 1993;19:144–9.
Beach JE, Faich G, Bormel G, Sasinowski FJ
. Black Box Warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J. 1998;53:403–11.
Hande RK, Noone RM, Stome WJ
. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.
Schoenenberger RA, Tanasijevic MJ, Jha A, Bates DW
. Appropriateness of antiepileptic drug level monitoring. JAMA. 1995;274:1622–6.
Roblin DW, Nielsen DM. Assessment of quality in adult primary care: developing process measures from administrative data. Clin Perform Qual Health Care. 1994;2:200–8.
Graham DJ, Drinkard DR, Shatin D. Study of liver enzyme monitoring in patients receiving troglitazone. Pharmacoepidemiol Drug Saf. 2000;(suppl 1):S131.
Emslie-Smith AM, Boyle DI, Evans JM, et al.
Contraindications to metformin therapy in patients with type 2 diabetes: a population-based study of adherence to prescribing guidelines. Diabet Med. 2001;18:483–8.
Abookire SA, Karson AS, Fiskio J, Bates DW
. Use and monitoring of “statin” lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001;161:53–8.
Tegeder I, Levy M, Muth-Selbach U, et al.
Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol. 1999;47:557–64.
Selby JV, Ettinger B, Swain BE
. First 20 months experience with use of metformin for type 2 diabetes in a large HMO. Diabetes Care. 1999;22:38–44.
Calabrese AT, Coley KC, DaPos SV, et al.
Risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434–7.
Graham DJ, Drinkard DR, Shatin D, et al.
Liver enzyme monitoring in patients receiving troglitazone. JAMA. 2001;286:831–3.
Chan KA, Davis RL, Gunter MJ, et al. The HMO Research Network. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Chichester, UK: Wiley; 2005 (in press).
Simon SR, Chan KA, Soumerai SB, et al.
Potentially inappropriate medication use among elderly persons in the United States HMOs, 2000–2001. J Am Geriatr Soc. 2005;53:227–32.
Physician’s Desk Reference. 54th ed. Montvale, NJ: Medical Economics Company Inc.; 2000.
Food and Drug Administration. http://www.fda.gov/medwatch/safety/2000/safety00.htm.
Baker DW, Chin MH, Cinquegrani MP, et al.
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol. 2001;38:2101–13.
Generali JA. Black box drug warnings: analgesics, anticonvulsants and anti-infectives. Hosp Pharm. 2002;37:1006–23.
Generali JA. Black box drug warnings: antineoplastics, vitamins and miscellaneous agents. Hosp Pharm. 2002;37:1228–46.
McEvoy GK, ed. AHFS Drug Information 1999. Bethesda, MD: American Society of Health-System Pharmacists; 1999.
Micromedex® Healthcare Series. Thomson Micromedex. Greenwood Village, Colo (Edition expires 06/2002).
Clark DO, Von Korff M, Saunders K, et al.
A chronic disease score with empirically derived weights. Med Care. 1995;33:783–95.
. Withdrawal of troglitazone and cisapride. JAMA. 2000;283:2228.
Poon EG, Gandhi TK, Sequist TD, et al.
I wish I had seen this test result earlier: dissatisfaction with test result management systems in primary care. Arch Intern Med. 2004;164:2223–8.
Schiff GD, Klass D, Peterson J, Shah G, Bates DW
. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Arch Intern Med. 2003;163:893–900.
Shabot MM, LoBue M, Chen J. Wireless clinical alerts for physiologic, laboratory and medication data. Proc AMIA Symp 2000:789–93.
Rind DM, Safran C, Phillips RS, et al.
Effect of computer-based alerts on the treatment and outcomes of hospitalized patients. Arch Intern Med. 1994;154:1511–7.
Raschke RA, Goldihare B, Wunderlich TA, et al.
A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. JAMA. 1998; 280:1317–20.
PubMed CrossRef Copyright information
© Society of General Internal Medicine 2005